Gsk Share Discussion Threads

[woodhawk] 11/5/2017 12:30

I went to China in 1992 - amongst the first mover Western brands I noticed already in Beijing and Shanghai were MacDonalds and PizzaHut.

[essentialinvestor] 11/5/2017 12:10

Western diet monty being increasingly adopted.

[montyhedge] 11/5/2017 12:07

Went to Japan last year, a lot of chinese visit there, what I notice how fat the chinese are getting eating junk food, I reckon china ticking time bomb for health issues. GSK will expand into china.

[essentialinvestor] 11/5/2017 11:56

Alp, yes I never take it for granted, very lucky indeed these medications
are available, Ventolin was very late 60's from memory.

[alphorn] 11/5/2017 11:54

Essential - I have had serious asthma from childhood - emergency hospital to home etc.. I agree that GSK's medication from the days of Ventolin in 1971 (?) are truly miraculous.
I have seen the clinical trial data from the later medication and some of it was amazing.

[essentialinvestor] 11/5/2017 11:43

If you don't have asthma it may be difficult to appreciate how great
a medication seretide is.

Have a chest cold atm and yesterday my blue/brown inhaler combo was not
working effectively, without seretide to fall back on it would have
been an A&E visit.

[montyhedge] 11/5/2017 11:19

Best dividend payer, cheque on doormat every 13 weeks, nice.

[woodhawk] 11/5/2017 11:10

Daily Mail today:

"Without a generic substitute for Advair in the U.S. market this year, GSK has said it expects adjusted 2017 earnings per share (EPS) to rise by between 5 and 7 percent, in constant currencies. If they had launched by mid-year, it had forecast EPS would be flat to slightly lower."

[ny boy] 11/5/2017 09:59

Added more at 1612p support

[montyhedge] 11/5/2017 09:19

Another divi in the bag, next one 13 weeks time, nice.

[ianood] 11/5/2017 08:59

Skyepharma (now VEC working with Mylan) had a torrid time with the FDA and flutiform and finally gave up!

[fangorn2] 11/5/2017 08:37

Generic drug maker Mylan NV on Wednesday said it disagrees with the reasoning behind the U.S. Food and Drug Administration's decision not to approve its generic for GlaxoSmithKline Plc's blockbuster Advair in March.

"Great way to engender ppsitive relations with FDA - Mylan competitor drug could be even further away that previously expected"

[montyhedge] 11/5/2017 08:32

Ex today so in theory up 17p, bears are slaughtered.

[dr biotech] 11/5/2017 08:29

Another 6 months before Advair falls off the patent cliff - thats got to be worth about 500m or so I guess.

[woodhawk] 11/5/2017 08:27

Non-approval and delays in leading generic competition for Advair should drive share price much higher, imo. As per today's news "Hikma's generic Advair faces U.S. delay, 2017 approval unlikely - The company said there was a low likelihood of approval this year."

[ny boy] 11/5/2017 08:17

Ex div today, holding up well, onwards to 1715p

[garycook] 11/5/2017 06:32

Monty,You are an expert on prediction,s.Of course the GBP will recover.£20 is my Target for GSK long term.

[montyhedge] 10/5/2017 15:49

The new guy appointed head of FDA by Trumps is the best news for pharma's I reckon.
Consultant for GSK for a year as well, he knows us, lol

[montyhedge] 10/5/2017 14:54

I spoke to a expert in currency trading he said $1.38 is a cert.

[ny boy] 10/5/2017 14:29

I guess if an overseas predator is looking at these, they might want to consider moving soon ..as £ set to rise to at least 13500 against US$ etc.

[montyhedge] 10/5/2017 13:49

badtime
Yes ex consultant to GSK now head of FDA, lol

[ny boy] 10/5/2017 13:45

No 1715p is resistance, don't forget the odd 15p :-)

Rising rsi too

[toffeeman] 10/5/2017 13:31

Toffeeman

Buy and hold - keep holding and short at 17 as a resistance trade.

[badtime] 10/5/2017 13:30

Upgraded from yesterday's forecast then Monty

[montyhedge] 10/5/2017 13:07

Montyhedge 2,050.00